Today, 4 clinical applications for class 1 new drugs are accepted

Today's guide 1) the clinical application of cbp-307 raw materials and capsules of kangnaide Biology (Shanghai) and Suzhou kangnaide biology was accepted The drug is a S1P1 agonist intended to treat a variety of different autoimmune diseases, including multiple sclerosis, psoriasis and inflammatory bowel disease On January 8, 2016, Suzhou kangnaide announced the successful completion of phase 1b clinical study of cbp-307, a leading drug promoted by its subsidiary kangnaide Australia 2) The clinical application of class 1 recombinant human PD-L1 monodomain antibody Fc fusion protein injection for therapeutic biological products of Suzhou Kangning jerui biology and Sichuan thingdi Pharmaceutical Co., Ltd has been accepted, and it is the first successful clinical application of PD-L1 monoclonal antibody in China The development code of the drug is kn035, which is composed of two functional regions: the single domain antibody (DAB) region and the human immunoglobulin crystallizable region (FC) The DAB region can bind human PD-L1 protein with high affinity and specificity The molecular weight of the whole antibody is smaller and more stable than other human antibodies It is a second-generation PD-L1 antibody drug On the one hand, it inherits the advantages of the first generation of PD-L1 antibody drugs, such as high efficacy, low toxicity and side effects, and high tumor targeting On the other hand, kn035 has the characteristics of high affinity, better preclinical efficacy, fast tumor targeting, long retention time, good preparation stability, etc it can use more convenient subcutaneous administration This antibody has advanced manufacturing technology and low production cost, which are the unique advantages of kn035 3) the clinical application of class 1.1 jackotinib dihydrochloride monohydrate and jackotinib hydrochloride tablets of Suzhou Zejing biology and Shanghai Zejing medicine was accepted, another TiNi! 4) the clinical application of hy-021068 of chemical medicine 1.1 of Hefei medical engineering medicine, Guangzhou boten biology and Nanjing Medical Engineering medicine was accepted, and the relevant information is not known at present.